NEW YORK – Phio Pharmaceuticals and AgonOx on Monday said they will collaborate on the development of T cell-based immunotherapies by combining Phio's lead product, the self-delivering RNAi compound PH-762, and AgonOx's "double positive" tumor-infiltrating lymphocyte (TIL) technology.
In preclinical studies, the companies have shown that treating "double positive" CD8 TILs with PH-762 improves their ability to kill tumor cells. Phio and AgonOx are planning to advance PH-762-treated "double positive" TILs into a clinical study and begin enrollment later this year.